Chronic Constipation, Methanogenesis Clinical Trial
Official title:
Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation
| NCT number | NCT01190020 |
| Other study ID # | MS-LUB-106 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 1 |
| First received | |
| Last updated | |
| Start date | February 2009 |
| Est. completion date | March 2012 |
| Verified date | July 2018 |
| Source | Augusta University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Lubiprostone, a chloride channel activator, has been shown to improve symptoms of chronic
constipation, largely by enhancing chloride-rich intestinal fluid secretion. Whether
Lubiprostone has effects on colonic methanogenesis is not known. The investigators
hypothesize that the effects of Lubiprostone may in part be due to its effects on altering
colonic flora, particularly methanogenic flora.
By altering the colonic stasis of stool and through more efficient clearance of digestive
residue, the investigators anticipate that Lubiprostone may either inhibit or promote better
excretion of methanogenic flora, and thereby decrease the gut load of methane producing
bacteria. In turn, this may lead to enhanced colonic smooth muscle contraction and an
increased rate of spontaneous bowel movements and reduction of constipation symptoms.
The aim is to investigate the effects of Lubiprostone on intestinal methane production and
bowel symptoms in patients with chronic constipation, by performing a randomized, double
blind, placebo controlled study.
| Status | Completed |
| Enrollment | 41 |
| Est. completion date | March 2012 |
| Est. primary completion date | March 2012 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Constipation as defined by Rome III criteria13. Patients must have symptoms > 3 days/month for the past three months and report at least two of the following symptoms = 25% of the time: straining, lumpy or hard stool, sensation of incomplete evacuation, sensation of anorectal obstruction/blockage, use of manual maneuvers, < 3 bowel movements/week. Also,they should have insufficient criteria for IBS, and only rarely loose stools without the use of laxatives. - = 3 ppm methane value at baseline1, 2(before sugar load). Exclusion Criteria: - Patients taking drugs that are known to be constipating will be excluded or asked to discontinue medications for at least 2 weeks and reassessed. For example, we will recommend that patients taking calcium channel antagonists contact their respective primary care physicians to explore alternative medications for hypertension such as beta blockers or ACE-inhibitors. If the calcium channel antagonists are able to be discontinued, patients will be re-screened at least two weeks after the medications are discontinued. If patients no longer meet inclusion criteria, they will be excluded from the study. Patients who remain constipated will be eligible for enrollment. - Patients with co-morbid illnesses such as severe cardiovascular disease, chronic renal failure, or those with previous gastrointestinal surgery except cholecystectomy and appendectomy - Patients with neurologic diseases such as multiple sclerosis, strokes, spinal cord injuries, and those who have problems with cognizance, i.e. a mini-mental score of <15 and/or are legally blind will be excluded. - Women who are pregnant or are likely to conceive during the course of the study will be excluded. Urinary pregnancy tests will be performed on all women of child-bearing potential prior to enrollment and before any x-ray of the abdomen. - Patients with Hirschsprung' s disease, or active local anorectal problems such as anal fissures, bleeding hemorrhoids, Crohn's, colitis, or colon cancer. - Patients with alternating constipation and diarrhea and those who fulfill the Rome-III criteria for irritable bowel syndrome. - Recent antibiotic use (last 6 weeks). - Patients using laxatives, PEG or Tegaserod and unwilling to discontinue these medications at least 2 weeks prior to the study. |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
| United States | University of Utah | Salt Lake City | Utah |
| Lead Sponsor | Collaborator |
|---|---|
| Augusta University | Takeda Pharmaceuticals North America, Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in Methane Production | Change in the mean area under the curve of the breath hydrogen and methane gas profiles in parts per million, from time 0 to 120 minutes, between baseline versus mean area under the curve at the end of study. | Baseline and 1 month | |
| Secondary | Stool Frequency (Complete Spontaneous Bowel Movements) | change in mean stool frequency (delta) between baseline week and final week of study | Baseline and 1 month | |
| Secondary | Percentage Change in the Colonic Transit Time | Percentage change of colonic transit time between the baseline colonic transit study and the colonic transit study at the end of study | Baseline and 1 month | |
| Secondary | Peak Methane Value | The peak methane value measured during the baseline breath study will be compared with the peak methane obtained at the end of study breath test | Baseline and 1 month |